STEROID

View as:
  • Alphabol

    $43.00 $38.00

    Manufacturer: Alpha Pharma
    Substance: Dianabol (Methandrostenolone, Methandienone)
    Package: 30 x 25mg tabs

    Add to cart
  • Anabol 500 tabs-cheap adult drugs

    $255.00

    Manufacturer: British Dispensary
    Category: Oral Steroids
    Substance: Dianabol (Methandrostenolone, Methandienone)
    Package: 500 Tablets 10 mg

    Add to cart
  • Anavar – Oxandrolone

    $90.00 $80.00

    Manufacturer: Generics Pharma
    Category: Oral Steroids
    Substance: Anavar (Oxandrolone)
    Package: 100 tabs. 10 mg

    Add to cart
  • Boldaxyl 300 -10ml/vial

    $44.00
    • Pharmaceutical Form
    • Drug Class: Anabolic Steroid (for intramuscular injection)
    • Active Life: 15 days
    • Average Dose: Men 200-600 mg/week, Women 50-100 mg/week
    • Liver Toxicity: None
    • Aromatization rate: Low
    • DHT Conversion: Low
    • Decrease HPTA function: Moderate
    • Anabolic/ Androgenic rate: 100:50
    • Active Substance:

      Boldenone Undecylenate 300mg/ml

    Add to cart
  • Boldebolin 250 10 X ampule 1ml (250mg)

    $45.00

    Manufacturer: Alpha Pharma
    Category: Injectable Steroids
    Substance: Equipoise (Boldenone Undecylenate)
    Package: 10 x 1ml ampules, 250mg/ml

    SKU: boldebolin. Category: Injectable Steroids.
    Add to cart
  • Dianabol 10 mg with discount

    $60.00 $55.00

    Category: Oral Steroids
    Substance: Dianabol (Methandrostenolone, Methandienone)
    Package: 10mg : 100 Tablets

    Add to cart
  • Dianoxyl 50- 50tabs/pack

    $35.00

     

    • Drug Class: Oral Anabolic Androgenic Steroid
    • Active Life: 6-8hours
    • Average Dose: 25-50 mg/day
    • Liver Toxicity: High
    • Aromatization rate: High
    • DHT Conversion: None
    • Decrease HPTA function: Yes
    • Anabolic/ Androgenic rate: 90-210 : 40-60
    • Active Substance:

      Methandienone 10mg/tab

     

    Add to cart
  • Duraxyl 100- 10ml/vial

    $35.00
    • Duraxyl 100

      Injectable Anabolic Steroid
      Active substance: Nandrolone Phenylpropionate
      Manufacturer: Kalpa Pharmaceuticals Ltd.
      Unit: 10 mL vial (100 mg/mL)

    Add to cart
  • HCG 5000iu*5vials

    $80.00 $79.00

    Brand Name: Provigil 5000
    Also Known As:  HCG, Provigil, gonadotropin
    Manufacturer: Organon laboratories.
    Quantity: 1x ampule  5000 IU

    Active Ingredient: Human chorionic gonadotropin

    Price is as Per Kit

    Add to cart
  • HUMATROPE *Somatropin* 36 IU (12MG)

    HUMATROPE®
    [somatropin (rDNA ORIGIN)] for Injection

    DESCRIPTION

    Humatrope (somatropin, rDNA origin, for injection) is a polypeptide hormone of recombinant DNA origin. Humatrope is synthesized in a strain of Escherichia coli that has been modified by the addition of the gene for human GH. The peptide is comprised of 191 amino acid residues and has a molecular weight of about 22,125 daltons. The amino acid sequence of the peptide is identical to that of human GH of pituitary origin.

    Humatrope is a sterile, white, lyophilized powder intended for subcutaneous or intramuscular administration after reconstitution to its liquid form. Humatrope is a highly purified preparation. Phosphoric acid and/or sodium hydroxide may have been added to adjust the pH. Reconstituted solutions have a pH of approximately 7.5. This product is oxygen sensitive.

    Vial

    Each vial of Humatrope contains 5 mg somatropin (15 IU or 225 nanomoles); 25 mg mannitol; 5 mg glycine; and 1.13 mg dibasic sodium phosphate. Each vial is supplied in a combination package with an accompanying 5-mL vial of diluting solution (diluent). The diluent contains Water for Injection with 0.3% metacresol as a preservative and 1.7% glycerin.

    Cartridge

    Cartridges of Humatrope contain either 6 mg (18 IU), 12 mg (36 IU), or 24 mg (72 IU) of somatropin. Each Humatrope cartridge contains the following:

     

    Cartridge
    6 mg (gold) 12 mg (teal) 24 mg (purple)
    Component
    Somatropin 6 mg 12 mg 24 mg
    Mannitol 18 mg 36 mg 72 mg
    Glycine 6 mg 12 mg 24 mg
    Dibasic sodium phosphate 1.36 mg 2.72 mg 5.43 mg

    Each cartridge is supplied in a combination package with an accompanying syringe containing approximately 3 mL of diluting solution (diluent). The diluent contains Water for Injection; 0.3% metacresol as a preservative; and 1.7%, 0.29%, and 0.29% glycerin in the 6, 12, and 24 mg cartridges, respectively.

    INDICATIONS

    Pediatric Patients

    HUMATROPE is indicated for the treatment of pediatric patients with:

    • growth failure due to inadequate secretion of endogenous growth hormone (GH),
    • short stature associated with Turner syndrome,
    • Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range,
    • short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency,
    • short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age.

    Adult Patients

    HUMATROPE is indicated for the replacement of endogenous GH in adults with GH deficiency.

    DOSAGE AND ADMINISTRATION

    Administration And Use Instructions

    • Therapy with HUMATROPE should be supervised by a physician who is experienced in the diagnosis and management of patients with the conditions for which HUMATROPE is indicated [see INDICATIONS AND USAGE].
    • Fundoscopic examination should be performed routinely before initiating treatment with HUMATROPE to exclude preexisting papilledema, and periodically thereafter [see WARNINGS AND PRECAUTIONS].
    • Leave HUMATROPE at room temperature for 10 minutes prior to administration.
    • Administer HUMATROPE by subcutaneous injection to the back of the upper arm, abdomen, buttock, or thigh with regular rotation of injection sites to avoid lipoatrophy.

    Pediatric Dosage

    • Individualize dosage for each patient based on the growth response.
    • Divide the calculated weekly HUMATROPE dosage into equal doses given either 6 or 7 days per week.
    • The recommended weekly dose in milligrams (mg) per kilogram (kg) of body weight for pediatric patients is:
      • Pediatric GH Deficiency: 0.18 mg/kg/week to 0.3 mg/kg/week (0.026 to 0.043 mg/kg/day)
      • Turner Syndrome: Up to 0.375 mg/kg/week (up to.054 mg/kg/day)
      • Idiopathic Short Stature: Up to 0.37 mg/kg/week (up to 0.053 mg/kg/day)
      • SHOX Deficiency: 0.35 mg/kg/week (0.05 mg/kg/day)
      • Small for Gestational Age (SGA): Up to 0.47 mg/kg/week (up to 0.067 mg/kg/day)
        • In very short pediatric patients, height SDS less than -3, and older pubertal pediatric patients consider initiating treatment with a larger dose of HUMATROPE (up to 0.067 mg/kg/day). Consider a gradual reduction in dosage if substantial catch-up growth is observed during the first few years of therapy. In pediatric patients less than 4 years of age with less severe short stature, baseline height SDS values between -2 and -3, consider initiating treatment at 0.033 mg/kg/day and titrate the dose as needed.
    • Assess compliance and evaluate other causes of poor growth such as hypothyroidism, under-nutrition, advanced bone age and antibodies to recombinant human GH if patients experience failure to increase height velocity, particularly during the first year of treatment.
    • Discontinue HUMATROPE for stimulation of linear growth once epiphyseal fusion has occurred [see CONTRAINDICATIONS].

    Adult Dosage

    • Patients who were treated with somatropin for GH deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin for GH deficient adults.
    • Consider using a lower starting dose and smaller dose increment increases for geriatric patients as they may be at increased risk for adverse reactions with HUMATROPE than younger individuals [see Use In Specific Populations].
    • Women may require higher doses and patients receiving oral estrogen may require higher doses [see DRUG INTERACTIONS].
    • Administer the prescribed dose daily.
    • Either of two HUMATROPE dosing regimens may be used:
      • Non-weight based:
        • Initiate HUMATROPE with a dose of approximately 0.2 mg/day (range, 0.15 mg/day to 0.3 mg/day) and increase the dose every 1-2 months by increments of approximately 0.1 mg/day to 0.2 mg/day, according to individual patient requirements based on the clinical response and serum insulin-like growth factor 1 (IGF-1) concentrations.
        • Use the patient’s clinical response, adverse reactions, and determination of age-and gender-adjusted serum IGF-1 concentrations as guidance in dose titration.
        • Maintenance dosages will vary considerably from person to person, and between male and female patients.
      • Weight-based:
        • Initiate HUMATROPE at 0.006 mg/kg daily and increase the dose according to individual patient requirements to a maximum of 0.0125 mg/kg daily.
        • Use the patient’s clinical response, adverse reactions, and determination of age-and gender-adjusted serum IGF-1 concentrations as guidance in dose titration.
        • Maintenance dosages will vary considerably from person to person, and between male and female patients
        • Not recommended for obese patients as they are more likely to experience adverse reactions with this regimen.

    Reconstitution Of Vials

    • Reconstitute the 5-mg vial of HUMATROPE with 1.5 to 5 mL of Diluent for HUMATROPE.
      • Inject the diluent into the vial by aiming the stream of liquid gently against the vial wall. Swirl the vial (do not shake) with a gentle rotary motion until the powder is completely dissolved into liquid and the solution is clear.
      • Inspect visually for particulate matter and discoloration. If the resulting solution is cloudy or contains particulate matter do not use.
    • Vials of HUMATROPE are stable for up to 14 days when reconstituted with Diluent for HUMATROPE and refrigerated at 36° to 46°F (2° to 8°C). Do not leave reconstituted vials at room temperature more than 30 minutes per day. Avoid freezing the reconstituted vial of HUMATROPE. Protect HUMATROPE from light during storage.
    • For patients with known hypersensitivity to the Diluent for HUMATROPE [see WARNINGS AND PRECAUTIONS], reconstitute the vial with Sterile Water for Injection. Use only one dose per vial, use immediately and discard the unused portion.

    Reconstitution Of Cartridges

    • Each HUMATROPE cartridge is designed for use only with the appropriate corresponding HumatroPen®.
      • Reconstitute each cartridge of HUMATROPE using only the diluent syringe that accompanies the cartridge. Do not shake. The reconstituted solution should be clear.
      • Inspect visually for particulate matter and discoloration. If the resulting solution is cloudy or contains particulate matter do not use.
      • The somatropin concentrations for the reconstituted HUMATROPE cartridges are as follows:

     

    Cartridge Somatropin Concentration
    6 mg 2.08 mg/mL
    12 mg 4.17 mg/mL
    24 mg 8.33 mg/mL

     

    • Reconstituted cartridges of HUMATROPE are stable for up to 28 days when refrigerated at 36° to 46°F (2° to 8°C). Do not leave at room temperature more than 30 minutes per day. Avoid freezing the reconstituted cartridge. Protect HUMATROPE from light during storage.
    • For patients with known hypersensitivity to the diluent supplied with the HUMATROPE cartridge [see WARNINGS AND PRECAUTIONS], do not use HUMATROPE cartridge. Use the HUMATROPE vial and reconstitute with Sterile Water for Injection [see DOSAGE AND ADMINISTRATION].

    HOW SUPPLIED

    Dosage Forms And Strengths

    HUMATROPE for injection is a white lyophilized powder available in the following vial and cartridge sizes:

    • 5 mg vial and a 5-mL vial of Diluent for HUMATROPE
    • 6 mg cartridge (gold) and a prefilled syringe of Diluent for HUMATROPE
    • 12 mg cartridge (teal) and a prefilled syringe of Diluent for HUMATROPE
    • 24 mg cartridge (purple) and a prefilled syringe of Diluent for HUMATROPE

    HUMATROPE for injection is a white lyophilized powder available in the following vial and cartridge sizes:

     

    NDC Kit HUMATROPE Diluent
    NDC 0002-7335-11 Vial Kit 5 mg vial 5-mL vial of Diluent for HUMATROPE
    NDC 0002-8147-01 Cartridge Kit 6 mg cartridge (gold) prefilled syringe of Diluent for HUMATROPE
    NDC 0002-8148-01 Cartridge Kit 12 mg cartridge (teal) prefilled syringe of Diluent for HUMATROPE
    NDC 0002-8149-01 Cartridge Kit 24 mg cartridge (purple) prefilled syringe of Diluent for HUMATROPE

     

    Storage And Handling

    Vials

    Refrigerate vials of HUMATROPE and Diluent for HUMATROPE at 36° to 46°F (2° to 8°C). Avoid freezing Diluent for HUMATROPE. Protect HUMATROPE from light during storage.

    Cartridges

    Refrigerate cartridges of HUMATROPE and Diluent for HUMATROPE at 36° to 46°F (2° to 8°C). Avoid freezing Diluent for HUMATROPE. Protect HUMATROPE from light during storage.

    SIDE EFFECTS

    The following important adverse reactions are also described elsewhere in the labeling:

    Clinical Studies Experience

    Because clinical studies are conducted under varying conditions, adverse reaction rates observed during the clinical studies performed with one somatropin formulation cannot always be directly compared to the rates observed during the clinical studies performed with a different somatropin formulation, and may not reflect the adverse reaction rates observed in practice.

    Pediatric Patients

    Growth Failure Due To Inadequate Secretion Of Endogenous Growth Hormone

    In an uncontrolled open-label study, 314 treatment-naive children aged >2 years who had GH deficiency were treated with HUMATROPE (0.06 mg/kg 3 times per week) for up to 8 years. Adverse reactions of special interest are reported in Table 1.

    Table 1: Adverse Reactions of Special Interest Occurring in Humatrope-Treated Patients with Growth Failure Due to Inadequate Secretion of Endogenous Growth Hormone in an Open-label Study for Up to 8 Years

     

    Adverse Reaction HUMATROPEa
    (n=314)
    Hypothyroidism 25%
    Allergic reaction 11%
    Arthralgia 6%
    Bone disorder 4%
    Edema 4%
    Injection site pain/reaction 4%
    Neoplasm/tumor 2%
    Cardiovascular disorders 1%
    Thyroid disorders 1%
    Intracranial hypertension 0%b
    Dose=0.06 mg/kg 3 times per week for up to 8 years.
    b n=1

     

    Short Stature Associated With Turner Syndrome

    In a randomized, concurrent-controlled (untreated), open-label study until attainment of adult height, the adverse reactions of special interest occurring in 74 patients treated with Humatrope at dose 0.3 mg/kg/week (mean duration 4.1 years) and in 62 untreated patients (mean duration 3.7 years) are reported in Table 2. A similar increase in otitis media was observed in an 18-month placebo-controlled study.

    Table 2: Adverse Reactions of Special Interest Occurring in Patients with Turner Syndrome in an Open-labelStudy Until Attainment of Adult Height

     

    Untreated
    (n=62)
    HUMATROPE
    (n=74)
    Surgical procedure 27% 45%
    Otitis media 26% 43%
    Ear disorders 5% 18%

     

    Idiopathic Short Stature

    Adverse reactions occurring in a randomized, placebo-controlled study of HUMATROPE treatment (0.22 mg/kg/week) until attainment of adult height (mean duration of HUMATROPE treatment 3.7 years, mean duration of placebo treatment 3.3 years) are reported in Table 3. Mean fasting serum insulin concentration increased by 10% in the HUMATROPE treatment group at the end of treatment relative to baseline, but remained within the normal reference range.

    Table 3: Adverse Reactions Occurring in Patients with Idiopathic Short Stature Treated with HUMATROPE in a Randomized Placebo-controlled Study

     

    Placebo
    (n=31)
    HUMATROPE
    (n=37)
    Scoliosis 13% 19%
    Otitis media 7% 16%
    Hyperlipidemia 3% 8%
    Gynecomastia 3% 5%
    Hip pain 0 3%
    Arthralgia 3% 11%
    Arthrosis 7% 11%
    Myalgia 13% 24%
    Hypertension 0 3%

     

    In a dose-response study (239 patients treated for 2 years), among HUMATROPE dose groups [0.24 mg/kg/week (n=78), 0.37 mg/kg/week (n=83), 0.24 mg/kg/week for the first year and 0.37 mg/kg/week thereafter (n=78)], mean fasting blood glucose, mean glycosylated hemoglobin, and the incidence of elevated fasting blood glucose concentrations were similar. One patient developed glucose intolerance and high serum HbA1c.

    Short Stature Or Growth Failure In SHOX Deficiency

    Adverse reactions of special interest from a 2-year randomized, open-label study with HUMATROPE (0.35 mg/kg/wk) compared to no treatment are presented in Table 4. During the 2-year study period, the proportion of patients who had at least one IGF-I concentration greater than 2.0 SD above the age-and gender-appropriate mean was 10 of 27 (37%) for the HUMATROPE-treated group vs. 0 of 24 patients (0%) for the untreated group. The proportion of patients who had at least one IGFBP-3 concentration greater than 2.0 SD above the age and gender appropriate mean was 16 of 27 (59%) for the HUMATROPE treated group vs. 7 of 24 (29%) for the untreated group.

    Table 4: Adverse Reactions of Special Interest Occurring in Patients with SHOX Deficiency By Treatment Groupin an Open-label Study

     

    Untreated
    (n=25)
    HUMATROPE
    (n=27)
    Arthralgia 8% 11%
    Gynecomastiaa 0% 8%
    Excessive number of cutaneous nevi 0% 7%
    Scoliosis 0% 47%
    Percentage calculated for males only: Untreated (0/1), HUMATROPE (1/12)

     

    Small For Gestational Age (SGA) With No Catch-up Growth By Age 2-4 Years

    In a 2-year, multicenter, randomized study, 193 pediatric patients were treated with 2 different HUMATROPE treatment regimens: a fixed dose of 0.067 mg/kg/day (FHD group) or an individually adjusted dose regimen (IAD group; starting dose 0.035 mg/kg/day which could be increased as early as Month 3 to 0.067 mg/kg/day based on a validated growth prediction model). Reported adverse reactions included: common childhood infectious diseases, otitis media, headaches, and slipped capital femoral epiphysis (n=1. Six patients (4 in the FHD group and 2 in the IAD group whose dose was increased from 0.035 mg/kg/day to 0.067 mg/kg/day [one at Month 3 and one at Year 1]) had impaired fasting glucose at Year 2. Two of 6 had impaired fasting glucose during the study, and one discontinued HUMATROPE at month 15 as a consequence. At study completion, 20-25% of patients had serum IGF-I SDS values > +2.

    The following adverse reactions were reported from an observational study of 340 pediatric patients who received HUMATROPE with an average dosage of 0.041 mg/kg/day (maximum dose: 0.084 mg/kg/day) for an average of 3.0 years: type 2 diabetes mellitus (n=1), carpal tunnel syndrome (n=1) and an exacerbation of preexisting scoliosis (n=1).

    Adult Patients

    Adult-Onset GH Deficiency

    In the first 6 months of controlled blinded studies during which patients received either HUMATROPE or placebo, patients who received HUMATROPE experienced an increase in edema (17% vs. 4%) and peripheral edema (12% vs. 0%). Edema, muscle pain, joint pain, and joint disorder were reported early in therapy and tended to be transient or responsive to dosage titration.

    Two of 113 patients developed carpal tunnel syndrome after beginning maintenance therapy without a low dose (0.00625 mg/kg/day) lead-in phase. Symptoms abated in these patients after dosage reduction.

    Adverse reactions with ≥5% overall occurrence rate during 12 or 18 months of replacement therapy with HUMATROPE are shown in Table 5 (adult-onset patients) and in Table 6 (childhood-onset patients).

    Table 5: Adverse Reactions with ≥5% Overall Occurrence in Adult-Onset Growth Hormone-Deficient Patients Treated with HUMATROPE for 18 Months as Compared with 6-Month Placebo and 12-Month HUMATROPE Exposure

     

    Adverse Reaction 18 Months Exposure [Placebo (6 Months)/Humatrope (12 Months)]
    (n=44)
    18 Months Humatrope Exposure
    (n=52)
    Edema 11% 21%
    Arthralgia 14% 17%
    Paresthesia 14% 17%
    Myalgia 9% 14%
    Pain 14% 14%
    Peripheral edema 18% 12%
    Headache 7% 8%
    Hypertension 5% 8%
    Joint disorder 2% 6%
    Rhinitis 11% 13%
    Back pain 9% 10%
    Acne 0% 6%
    Surgical procedure 2% 6%
    Flu syndrome 7% 4%

     

    Childhood-Onset GH Deficiency

    Two double-blind, placebo-controlled studies were conducted in 67 adult patients who had received previous somatropin treatment during childhood. Patients were randomized to receive either placebo injections or HUMATROPE (0.00625 mg/kg/day for the first 4 weeks, then 0.0125 mg/kg/day thereafter) for the first 6 months, followed by open-label use of HUMATROPE for the next 12 months for all patients. During the placebo-controlled phase (first 6 months) of the study, elevations of serum glutamic oxaloacetic transferase were reported more for HUMATROPE-treated (13% vs. 0%) than placebo-treated patients.

    Table 6: Adverse Reactions with ≥5% Overall Occurrence in Childhood-Onset Growth Hormone-Deficient Patients Treated with HUMATROPE for 18 Months as Compared with 6-Month Placebo and 12-Month HUMATROPE Exposure

     

    Adverse Reaction 18 Months Exposure [Placebo (6 Months)/Humatrope (12 Months)]
    (n=30)
    18 Months Humatrope Exposure
    (n=32)
    ASTa increased 7% 13%
    Headache 7% 9%
    Asthenia 3% 6%
    Edema 10% 6%
    Myalgia 7% 6%
    Pain 10% 6%
    ALT a increased 7% 6%
    Flu syndrome 10% 16%
    Cough increased 0% 6%
    Hypesthesia 0% 6%
    Rhinitis 7% 6%
    Respiratory disorder 7% 3%
    Gastritis 7% 0%
    Pharyngitis 7% 3%
    Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase

     

    Immunogenicity

    As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to HUMATROPE with the incidence of antibodies to other products may be misleading.

    In a clinical study with HUMATROPE during the first 6 months of HUMATROPE therapy in 314 naive patients, 1.6% developed specific antibodies to HUMATROPE (binding capacity ≥0.02 mg/L). None had antibody concentrations which exceeded 2 mg/L. Throughout 8 years of this same study, two patients (0.6%) had binding capacity >2 mg/L. Neither patient demonstrated a decrease in growth velocity at or near the time of increased antibody production. It has been reported that growth attenuation from pituitary-derived GH may occur when antibody concentrations are >1.5 mg/L.

    Postmarketing Experience

    The following adverse reactions have been identified during post-approval use of HUMATROPE. Because these adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Severe Hypersensitivity Reactions – Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropin products

    Neurologic – Headaches (common in pediatric patients and occasional in adults)

    Skin – Increase in size or number of cutaneous nevi

    Endocrine – Gynecomastia

    Gastrointestinal – Pancreatitis

    Metabolic – New-onset type 2 diabetes mellitus

    Neoplasia – Leukemia has been reported in a small number of GH deficient pediatric patients treated with somatropin

    Drug Interactions
    Read more
  • Induject 250 10x ampule ( 250mg/ 1ml )

    $45.00

    Sustanon 250mg from Alpha Pharma.

    – 10x ampules (Original box)

    – 1 ampule (1ml) = 250mg

    – code to verify originality on the box

    Add to cart
  • Masteron V 100mg/ml injection

    $170.00

    Masteron V 100mg/ml vials/injections:

    Masteron V as it is often called, is most commonly used by bodybuilders who are in the cutting phase of their training and dieting

    You can buy Masteron V 100mg/ml injections online without prescription (No RX).

    product price is as: per vial
    Minimum order quantity is: 1 vials

    Add to cart

Showing 1–15 of 42 results